Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Adalimumab, Infliximab and Etanercept Biosimilars Market From 2025 to 2029?

In recent times, the nutritional serum market has seen a powerful growth. The market is projected to expand from a size of $6.33 billion in 2024 to $6.84 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 8.0%. The robust growth observed in the historic period can be credited to a rise in the elderly population, heightened consciousness about health and wellness, the growth of the sports and fitness industry, the ease of using serums, and an increased preference for clean beauty products.

In the near future, the market size of nutritional serum is anticipated to witness a significant surge. The market is projected to expand to “$9.44 billion by 2029, with a compound annual growth rate (CAGR) of 8.4%. This growth during the expected period can be attributed to the rising trend towards organic and natural ingredients, a shift towards preventive healthcare, an increase in veganism and vegetarianism, the proliferation of corporate wellness programs, and a focus on immune health. Key trends to watch during this period include the uptake of environmentally-friendly packaging solutions, the introduction of nutritional serums compatible with wearable health tech devices, advancements in formulation techniques, the emergence of subscription-based models, and progress in hybrid nutritional products.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18791&type=smp

What Elements Are Contributing To Growth In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

The accessibility of biosimilars in the adalimumab, infliximab, and etanercept biosimilars market has been driven by the expiration of patents on branded drugs. This includes in the United States, where Inflectra, produced by Hospira (owned by Pfizer Inc.), was sanctioned by the FDA for treating several autoimmune diseases, such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis. This followed the end of the patent on the branded drug, Remicade. In a similar case, the European Commission approved Benepali, a biosimilar of Amgen’s Enbrel, once its patent concluded in the EU. Following the termination of Humira’s patent, its biosimilars have been brought to market, with the FDA recently approving Hulio, Humira’s sixth biosimilar. Therefore, the conclusion of patents for branded biologic drugs like Humira, Enbrel, and Remicade is stimulating demand in the adalimumab, infliximab, and etanercept biosimilars market.

The nutritional serum market covered in this report is segmented –

1) By Type: Vitamin Serums, Antioxidant Serums, Hydrating Serums, Exfoliating Serums, Anti-Aging Serums, Brightening Serums, Anti-Acne Serums, Oil Control Serums, Skin-Tightening Serums, Other Types

2) By Skin Type: Dry Skin, Oily Skin, Normal Skin, Sensitive Skin

3) By Price: Low, Medium, High

4) By Distribution Channel: Online, Offline

5) By End Use: Men, Women

Subsegments:

1) By Vitamin Serums: Vitamin C Serums, Vitamin E Serums, Vitamin A (Retinol) Serums, Vitamin B Complex Serums, Other Vitamin-Infused Serums

2) By Antioxidant Serums: Green Tea Extract Serums, Niacinamide Serums, Resveratrol Serums, Coenzyme Q10 Serums, Other Antioxidant-Infused Serums

3) By Hydrating Serums: Hyaluronic Acid Serums, Glycerin-Based Serums, Aloe Vera Serums, Other Moisturizing Serums

4) By Exfoliating Serums: Alpha Hydroxy Acid (AHA) Serums, Beta Hydroxy Acid (BHA) Serums, Enzyme-Based Serums, Other Exfoliating Serums

5) By Anti-Aging Serums: Peptide-Based Serums, Retinol Or Retinoid Serums, Collagen-Boosting Serums, Other Anti-Aging Formulations

6) By Brightening Serums: Vitamin C-Based Serums, Niacinamide Serums, Licorice Extract Serums, Arbutin Serums, Other Brightening Serums

7) By Anti-Acne Serums: Salicylic Acid Serums, Benzoyl Peroxide Serums, Tea Tree Oil Serums, Sulfur-Based Serums, Other Acne-Fighting Serums

8) By Oil Control Serums: Salicylic Acid Oil Control Serums, Niacinamide Oil Control Serums, Clay-Based Serums, Other Oil Regulation Serums

9) By Skin-Tightening Serums: Collagen-Boosting Serums, Elastin-Enhancing Serums, Firming Peptide Serums, Other Skin Tightening Formulas

10) By Other Types: Custom Formulated Serums, Multi-Function Serums, Specialized Serums For Sensitive Skin

What Are The Leading Trends And Opportunities In The Adalimumab, Infliximab and Etanercept Biosimilars Sector?

Key players in the nutritional serum market are innovating with products like Vitamin serums to cater to the increasing consumer need for specific skincare solutions. Vitamin serums are skincare items enriched with higher proportions of vitamins such as Vitamin C, E or A, tailored to address specific skin issues like brightening, aging, and hydration. An example of this is Galderma S.A., a pharmaceutical company based in Switzerland, who in July 2024 introduced the Cetaphil Vitamin C Serum and Cetaphil Ceramide Serum. The Vitamin C Serum from Cetaphil is enriched with 3-O-ethyl ascorbic acid to offer antioxidant protection and reduce dark spots, while the Ceramide Serum incorporates ceramide, Centella Asiatica, and allantoin to bolster and repair the skin barrier, offering enhanced skin texture and 48-hour hydration.

Who Are The Key Contributors To Growth In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Major companies operating in the nutritional serum market are Procter & Gamble Company, Johnson & Johnson Services Inc., Unilever, L’Oréal S.A., Colgate-Palmolive, Estee Lauder Companies Inc., Beiersdorf AG, Shiseido Company Limited, Avon Products Inc., Coty Inc., Galderma S.A., Amorepacific Corporation, Mary Kay Inc., Nu Skin Enterprises, The Body Shop International Limited, KOSÉ Corporation, Revlon Inc., Melaleuca Inc., Young Living Essential Oils LC, Oriflame Holding AG, VLCC Health Care Limited, Natura Bisse International Inc., MamaEarth, Morrocanoil Inc., Tata Harper Skincare

https://www.thebusinessresearchcompany.com/report/nutritional-serum-global-market-report

Which Region Is Projected To Lead The Adalimumab, Infliximab and Etanercept Biosimilars Market By 2025?

Asia-Pacific was the largest region in the nutritional serum market in 2024. The regions covered in the nutritional serum market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=18791&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model